dizocilpine-maleate and Liver-Failure

dizocilpine-maleate has been researched along with Liver-Failure* in 2 studies

Other Studies

2 other study(ies) available for dizocilpine-maleate and Liver-Failure

ArticleYear
Blocking NMDA receptors delays death in rats with acute liver failure by dual protective mechanisms in kidney and brain.
    Neuromolecular medicine, 2014, Volume: 16, Issue:2

    Treatment of patients with acute liver failure (ALF) is unsatisfactory and mortality remains unacceptably high. Blocking NMDA receptors delays or prevents death of rats with ALF. The underlying mechanisms remain unclear. Clarifying these mechanisms will help to design more efficient treatments to increase patient's survival. The aim of this work was to shed light on the mechanisms by which blocking NMDA receptors delays rat's death in ALF. ALF was induced by galactosamine injection. NMDA receptors were blocked by continuous MK-801 administration. Edema and cerebral blood flow were assessed by magnetic resonance. The time course of ammonia levels in brain, muscle, blood, and urine; of glutamine, lactate, and water content in brain; of glomerular filtration rate and kidney damage; and of hepatic encephalopathy (HE) and intracranial pressure was assessed. ALF reduces kidney glomerular filtration rate (GFR) as reflected by reduced inulin clearance. GFR reduction is due to both reduced renal perfusion and kidney tubular damage as reflected by increased Kim-1 in urine and histological analysis. Blocking NMDA receptors delays kidney damage, allowing transient increased GFR and ammonia elimination which delays hyperammonemia and associated changes in brain. Blocking NMDA receptors does not prevent cerebral edema or blood-brain barrier permeability but reduces or prevents changes in cerebral blood flow and brain lactate. The data show that dual protective effects of MK-801 in kidney and brain delay cerebral alterations, HE, intracranial pressure increase and death. NMDA receptors antagonists may increase survival of patients with ALF by providing additional time for liver transplantation or regeneration.

    Topics: Animals; Blood-Brain Barrier; Body Temperature; Brain; Brain Edema; Cerebrovascular Circulation; Disease Progression; Dizocilpine Maleate; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Galactosamine; Glomerular Filtration Rate; Hepatic Encephalopathy; Hyperammonemia; Intracranial Hypertension; Inulin; Kidney; Lactates; Liver Failure; Liver Regeneration; Male; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Time Factors

2014
Binding of the ligand [3H]MK-801 to the MK-801 binding site of the N-methyl-D-aspartate receptor during experimental encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit.
    Metabolic brain disease, 1993, Volume: 8, Issue:2

    Binding of the ligand [3H]MK-801 to the MK-801 binding site of the N-methyl-D-aspartate (NMDA) receptor population on brain homogenates in rabbits was studied during experimental encephalopathy from acute liver failure and from acute hyperammonemia in the rabbit. Homogenates were prepared from brain cortex, hippocampus and striatum. Hepatic encephalopathy was induced by a two-stage liver devascularization procedure and acute hyperammonemia by a prolonged ammonium-acetate infusion; rabbits receiving a sodium-potassium-acetate infusion served as controls. In these animal models extracellular brain glutamate levels are known to be elevated. However no significant alterations in the number nor the affinity of the MK-801 binding sites of the NMDA receptors were found during acute liver failure and acute hyperammonemia. These findings suggest that the NMDA receptor population remains unaltered in experimental encephalopathy from acute liver failure and acute hyperammonemia, despite alterations in extracellular brain glutamate levels.

    Topics: Acute Disease; Ammonia; Animals; Binding Sites; Dizocilpine Maleate; Hepatic Encephalopathy; Liver Failure; Rabbits; Receptors, N-Methyl-D-Aspartate

1993